{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:00:44Z","timestamp":1793066444744,"version":"4.5.0"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum \u03b2-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-\u03b2-lactamase (MBL)-positive strains, has led to limited treatment options in these isolates. This study evaluated the activity of aztreonam-avibactam (ATM-AVI) and comparator antimicrobials against Enterobacterales isolates and key resistance phenotypes stratified by wards, infection sources and geographic regions as part of the ATLAS program between 2016 and 2020. Minimum inhibitory concentrations (MICs) were determined per Clinical and Laboratory Standards Institute (CLSI) guidelines. The susceptibility of antimicrobials were interpreted using CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. A tentative pharmacokinetic\/pharmacodynamic breakpoint of 8 \u00b5g\/mL was considered for ATM-AVI activity. ATM-AVI inhibited \u226599.2% of Enterobacterales isolates across wards and \u226599.7% isolates across infection sources globally and in all regions at \u22648 \u00b5g\/mL. For resistance phenotypes, ATM-AVI demonstrated sustained activity across wards and infection sources by inhibiting \u226598.5% and \u226599.1% of multidrug-resistant (MDR) isolates, \u226598.6% and \u226599.1% of ESBL-positive isolates, \u226596.8% and \u226590.9% of carbapenem-resistant (CR) isolates, and \u226596.8% and \u226597.4% of MBL-positive isolates, respectively, at \u22648 \u00b5g\/mL globally and across regions. Overall, our study demonstrated that ATM-AVI represents an important therapeutic option for infections caused by Enterobacterales, including key resistance phenotypes across different wards and infection sources.<\/jats:p>","DOI":"10.3390\/antibiotics12111591","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T10:51:28Z","timestamp":1699008688000},"page":"1591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016\u20132020"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-3691","authenticated-orcid":false,"given":"Denis","family":"Pi\u00e9rard","sequence":"first","affiliation":[{"name":"Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, B-1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Hermsen","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[{"name":"Pfizer International Operations, F-75668 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis F.","family":"Arhin","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Kirkland, QC H9J 2M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14656566.2021.1904891","article-title":"Escalating antimicrobial resistance among Enterobacteriaceae: Focus on carbapenemases","volume":"22","author":"Lynch","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of Infections Due to MDR Gram-Negative Bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10096-022-04400-z","article-title":"Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019\u20132020)","volume":"41","author":"Sader","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sheu, C.C., Chang, Y.T., Lin, S.Y., Chen, Y.H., and Hsueh, P.R. (2019). Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00080"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Noster, J., Thelen, P., and Hamprecht, A. (2021). Detection of Multidrug-Resistant Enterobacterales\u2014From ESBLs to Carbapenemases. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091140"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30319","DOI":"10.2807\/1560-7917.ES.2016.21.33.30319","article-title":"The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study","volume":"21","author":"Stewardson","year":"2016","journal-title":"Eurosurveillance"},{"key":"ref_7","unstructured":"(2023, June 15). Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3934\/microbiol.2020012","article-title":"Emerging superbugs: The threat of Carbapenem Resistant Enterobacteriaceae","volume":"6","author":"Dong","year":"2020","journal-title":"AIMS Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of Carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1001\/jama.2008.896","article-title":"Carbapenem-Resistant Enterobacteriaceae: A Potential Threat","volume":"300","author":"Schwaber","year":"2008","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13643-022-02110-3","article-title":"Prevalence and incidence of carbapenem-resistant K. pneumoniae colonization: Systematic review and meta-analysis","volume":"11","author":"Tesfa","year":"2022","journal-title":"Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3201\/eid2007.121004","article-title":"Deaths attributable to carbapenem-resistant Enterobacteriaceae infections","volume":"20","author":"Falagas","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.2147\/IDR.S390635","article-title":"Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review","volume":"15","author":"Hu","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.01222-13","article-title":"Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: Systematic evaluation of the available evidence","volume":"58","author":"Falagas","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xu, L., Sun, X., and Ma, X. (2017). Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann. Clin. Microbiol. Antimicrob., 16.","DOI":"10.1186\/s12941-017-0191-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/IDR.S244357","article-title":"Evaluation of Resistance Mechanisms in Carbapenem-Resistant Enterobacteriaceae","volume":"13","author":"Alizadeh","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e01076-18","DOI":"10.1128\/AAC.01076-18","article-title":"Past and Present Perspectives on \u03b2-Lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/14787210.2016.1106940","article-title":"Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE)","volume":"14","author":"Goodman","year":"2016","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Suay-Garc\u00eda, B., and P\u00e9rez-Gracia, M.T. (2019). Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030122"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00397-20","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2217\/fmb-2020-0193","article-title":"Epidemiology of extended-spectrum \u03b2-lactamase and metallo-\u03b2-lactamase-producing Escherichia coli in South Asia","volume":"16","author":"Islam","year":"2021","journal-title":"Future Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/AAC.00782-08","article-title":"Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections","volume":"53","author":"Daikos","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"de Jager, P., Chirwa, T., Naidoo, S., Perovic, O., and Thomas, J. (2015). Nosocomial Outbreak of New Delhi Metallo-\u03b2-Lactamase-1-Producing Gram-Negative Bacteria in South Africa: A Case-Control Study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123337"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1017\/S0950268819000256","article-title":"Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae","volume":"147","author":"Snyder","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: The versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum beta-lactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/ciz1159","article-title":"Aztreonam Combination Therapy: An Answer to Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacteria?","volume":"71","author":"Shields","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A Primer on AmpC \u03b2-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1128\/AAC.01989-12","article-title":"Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-\u03b2-lactamase producers","volume":"57","author":"Crandon","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","first-page":"70","article-title":"ESBL, MBL and Ampc \u03b2 Lactamases Producing Superbugs\u2014Havoc in the Intensive Care Units of Punjab India","volume":"7","author":"Oberoi","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/ijmm.IJMM_19_215","article-title":"Colistin-sparing approaches with newer antimicrobials to treat carbapenem-resistant organisms: Current evidence and future prospects","volume":"37","author":"Veeraraghavan","year":"2019","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: Results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","unstructured":"(2023, August 08). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03580044."},{"key":"ref_37","unstructured":"(2023, August 08). Available online: https:\/\/clinicaltrials.gov\/study\/NCT03329092."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00592-18","DOI":"10.1128\/AAC.00592-18","article-title":"In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jac\/dkaa504","article-title":"Aztreonam\/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019","volume":"76","author":"Sader","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jgar.2022.06.018","article-title":"In vitro activity of aztreonam\/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019","volume":"30","author":"Rossolini","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jgar.2020.08.004","article-title":"In vitro activity of aztreonam\/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017","volume":"24","author":"Esposito","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_43","unstructured":"ATLAS Surveillance (2023, April 21). Antimicrobial Testing Leadership and Surveillance. Available online: https:\/\/atlas-surveillance.com\/."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/jac\/dkv132","article-title":"Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: A novel approach for aztreonam\/avibactam","volume":"70","author":"Singh","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e01659-20","DOI":"10.1128\/AAC.01659-20","article-title":"Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-\u03b2-Lactamase-Producing Escherichia coli Isolates","volume":"64","author":"Sadek","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jgar.2021.01.010","article-title":"Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012\u20132017","volume":"24","author":"Estabrook","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","article-title":"Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019\u20132021)","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1128\/AAC.00107-16","article-title":"Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.02379-15","article-title":"Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-\u03b2-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jgar.2022.04.011","article-title":"Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020","volume":"30","author":"Karlowsky","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_52","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2023). Performance Standards for Antimicrobial Susceptibility Testing, CLSI. [33rd ed.]. CLSI Supplement M100."},{"key":"ref_53","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2023). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 13.0, The European Committee on Antimicrobial Susceptibility Testing. Available online: http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"dlab159","DOI":"10.1093\/jacamr\/dlab159","article-title":"Evaluation of the in vitro activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012\u201319","volume":"3","author":"Jamal","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/11\/1591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:16:32Z","timestamp":1760130992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/11\/1591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["antibiotics12111591"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12111591","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]}}}